Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]
In development
Reference number: GID-TA11385
Expected publication date: TBC
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early August 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.